DF/HCC SPORE in Lymphoma
PI: Philippe Armand, David Weinstock NOVEMBER 16, 2020
The DF/HCC Lymphoma and Myeloma Program is currently seeking applications for Translational Projects in Lymphoma for a new Specialized Program in Research Excellence (SPORE), with applications due on December 10, 2020. Read more about this award below for more information.
NEW Translational Projects In Lymphoma
The applicant (PI) or co-PI must be on the faculty at Harvard Medical School or Harvard School of Public Health at the level of Assistant Professor or higher. Research may span the disciplines of biology, population science, or clinical science. All basic research supported by the SPORE must have a plan for translation into application or studies in humans, since the purpose of this program is to promote translational research in lymphoma. Similarly, all clinical research needs to have a strong wet or dry lab component. As such, basic or population scientists need to partner with clinical scientists to ensure a plan for clinical application. Collaboration between investigators currently working in this field and across DF/HCC institutions is strongly encouraged but not required.
|AWARD AMOUNT:|| |
Up to $150k in yearly direct costs for up to 5 years
|KEY DATES|| |
APPLICATION DEADLINE: On or before December 10, 2020
We are seeking pre-applications in the form of a 1-page proposal that contains background, specific aims, research plan and plans for translation (see below). These pre-applications will be judged on their scientific merit, translational potential and the potential for contribution to the overall Lymphoma SPORE. A subset of pre-applications will be selected to present their proposal at a project review session (exact time and place to be determined). Up to 5 projects may ultimately be selected for inclusion in the SPORE application, which will be submitted in May 2021. Projects will receive funding at a level up to $150k in yearly direct costs for up to 5 years. Awardees will become members of the DF/HCC Lymphoma and Myeloma Program and will be expected to attend SPORE activities (meetings, retreats, research presentations). Women and minority candidates are encouraged to apply.
APPLICATIONS SHOULD CONSIST OF THE FOLLOWING:
- NIH Biosketch of all key personnel
- Current Other Support pages for all key personnel
- A brief research proposal of 1 page that is structured as follows:
- Specific Aims
- Research Plan
- Plan for Translation to Clinical Application
- References with links to relevant publications
Application Submission Instructions: One PDF document including the above required documentation should be emailed to Sara Hanley (SaraM_Hanley@dfci.harvard.edu) by December 10, 2020. For all inquiries, please contact David Weinstock (firstname.lastname@example.org) or Philippe Armand (Philippe_Armand@dfci.harvard.edu).